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Sir,
We appreciate the comments provided by Garantziotis (2011) on
our recent publication in British Journal of Cancer (Michlmayr
et al, 2010). In this study, we investigated whether the protein
expression profile in plasma samples from breast cancer patients
changes within a few days in response to the initial dose of
epirubicin/docetaxel therapy. The expression of several plasma
proteins was found to be modulated by the therapy, including
inter-a-trypsin inhibitor (IaI) and different members of the
complement cascade. We focused our attention on the comple-
ment components and might have underestimated the potential
importance of increased IaI levels.
IaI proteins are a family of structurally related serine protease
inhibitors with hyaluronan-binding capacities, assembled from a
light chain and one of five homologous heavy chains (H1–H5). In
correspondence, separation of IaI by two-dimensional gel electro-
phoresis results in different spots with a molecular weight of B80,
125 and 250kDa (Josic et al, 2006). In our study, we found that the
abundance of several 125kDa IaI spots (388, 393, 397, 405, 406 and
407) is influenced by the epirubicin/docetaxel therapy (see Figure 1A).
All these spots reacted nearly identical to the treatment. Figure 1B
shows the expression level of the IaI spot 405 before and after the
initial dose of epirubicin/docetaxel (time a and b, respectively).
The abundance of this spot increased in nearly all patients (n¼22;
increase¼32±28%). Garantziotis referred in his letter to a recently
found interaction of IaI with the complement system. In an experi-
mental study, he could show that IaI attenuates in vitro complement
activation and reduces in vivo complement-induced lung injury
(Garantziotis et al, 2007). This is of special interest with respect to
our findings. Our study revealed that the plasma level of total C3
decreases in response to epirubicin/docetaxel therapy (Figure 1C).
Comparing the abundances of IaI (spot 405) with the total plasma
C3 revealed that both parameters correlate negatively with each
other (Spearman’s Rho r¼ 0.49, Po0.01, n¼44). The total plasma
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Figure 1 Inter-a-trypsin inhibitor (IaI) in plasma samples. (A) Two-dimensional gel electrophoresis of plasma proteins indicating the 125kDa IaI spots.
(B) Standardised abundance of spot 405 before (time a) and after (time b) the initial dose of epirubicin/docetaxel given to 22 breast cancer patients.
(C) Plasma total levels of complement component C3, as determined by immunonephelometry.
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www.bjcancer.comC3 was measured by a routine nephelometric immunoassay that
cannot distinguish between the different C3 isoforms. In our study,
we also investigated the single isoforms of C3 by two-dimensional
gel electrophoresis. They responded unequally to the therapy and
some of them correlated with the tumour size at the end of treat-
ment. However, none of these single isoforms showed a correlation
with the IaI spots, and no 125kDa IaI spot showed a correlation
with the success of therapy.
Although these findings corroborate the interaction of IaI
and the complement system, several questions remain. Is the
therapy-induced increase in plasma IaI the causative factor for
C3 reduction? Is the decrease in C3 associated with reduced
complement reactivity? How do the other IaI isoforms (80 and
250kDa) react in response to therapy (they were not identified
on our 2D gels)? Further studies are needed to find satisfactory
answers.
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